Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 4588Pancreatic Neoplasms 2837Carcinoma, Hepatocellular 2473Stomach Neoplasms 2325Colonic Neoplasms 1790Rectal Neoplasms 1714Esophageal Neoplasms 1373Liver Neoplasms 920Neoplasms 913Breast Neoplasms 836Neoplasm Metastasis 761Carcinoma, Non-Small-Cell Lung 702Cholangiocarcinoma 581Lung Neoplasms 555Ovarian Neoplasms 533Esophageal Squamous Cell Carcinoma 510Gastrointestinal Neoplasms 494Melanoma 381Prostatic Neoplasms 371Biliary Tract Neoplasms 370Head and Neck Neoplasms 303Uterine Cervical Neoplasms 286Carcinoma, Renal Cell 282Adenocarcinoma Of Esophagus 273Sarcoma 263Squamous Cell Carcinoma of Head and Neck 262Gastrointestinal Stromal Tumors 251Endometrial Neoplasms 233Urinary Bladder Neoplasms 226Gallbladder Neoplasms 223

Interventions

camrelizumab 1apatinib 1Folfox protocol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Advanced Primary Liver Cancer × Gastrointestinal × Clear all
NCT03092895 2026-01-29

A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTC

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Completed
157 enrolled 17 charts
Gastrointestinal

Advanced Primary Liver Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡